Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through a biotech filing that runs 300 pages of clinical data is hard enough; add rare-disease terminology and Rhythm Pharmaceuticals’ disclosures become downright daunting. Whether you need the latest Rhythm Pharmaceuticals quarterly earnings report 10-Q filing or want to track Rhythm Pharmaceuticals insider trading Form 4 transactions before the next data read-out, the challenge is finding what matters fast.
Stock Titan solves that problem. Our AI reads every 10-K, 10-Q, 8-K and proxy statement the moment it posts to EDGAR and delivers plain-language highlights—think cash runway trends, pivotal-trial costs, and patent-expiry clocks—so you can focus on decisions, not deciphering jargon. Looking for Rhythm Pharmaceuticals annual report 10-K simplified? It’s already condensed. Need Rhythm Pharmaceuticals Form 4 insider transactions real-time? Alerts arrive in seconds.
- AI-powered summaries that answer “understanding Rhythm Pharmaceuticals SEC documents with AI” in minutes
- Real-time feeds for Rhythm Pharmaceuticals executive stock transactions Form 4
- Side-by-side comparison of sequential trials inside every 10-Q earnings report filing analysis
- Key excerpts from Rhythm Pharmaceuticals proxy statement executive compensation—RSUs, milestone bonuses and all
- Rhythm Pharmaceuticals 8-K material events explained in plain English, from FDA label updates to financing rounds
Investors use these insights to monitor insider sentiment ahead of top-line data, gauge cash burn vs. runway, and benchmark executive incentives against regulatory goals. No more scrolling line-by-line; our platform surfaces what biopharma specialists actually need—from patient enrollment numbers to royalty obligations—so your biotech diligence stays sharp and timely.
Hunter C. Smith, Chief Financial Officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported option exercises and share sales on August 12-13, 2025. The filing shows Mr. Smith exercised 24,611 stock options at an exercise price of $6.88 on August 12, 2025, and 3,477 options at the same exercise price on August 13, 2025, resulting in 28,088 shares underlying those exercises.
Concurrent with the August 12 exercise, 24,611 shares were sold under a Rule 10b5-1 plan at a weighted-average price of $96.3322 per share (individual sale prices ranged $96.00–$96.63). On August 13, 3,477 shares were sold at $96.00 per share. After these transactions the reporting person owned 116,915 shares beneficially. The Form 4 notes the 10b5-1 plan was adopted February 28, 2025, and the stock options were fully vested.
Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals (RYTM), reported buy and sell transactions on 08/12/2025. The Form 4 shows acquisitions of 1,000 shares at $17.97 and 500 shares at $49.23, and a sale of 1,500 shares at $95. Following these transactions, the reporting person beneficially owned 922 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted March 11, 2025. The filing also discloses outstanding stock options: 1,000 options (exercise price $17.97) exercisable beginning 04/03/2033 and 500 options (exercise price $49.23) exercisable beginning 02/15/2034, with detailed vesting schedules provided.
RA Capital and affiliated persons reported ownership of 5,561,359 shares of Rhythm Pharmaceuticals, Inc. common stock, equal to 8.7% of the class based on 63,621,472 shares outstanding as of April 30, 2025. The filing lists the Fund (RA Capital Healthcare Fund, L.P.) as the direct holder of the 5,561,359 shares and states that RA Capital Management, L.P. serves as the Fund's investment adviser with delegated sole power to vote and dispose of the Fund's holdings, although the Fund disclaims beneficial ownership for Section 13(d) purposes because that delegation may not be revoked on less than 61 days' notice. The Reporting Persons expressly disclaim status as a group. The filing includes the issuer's principal office address in Boston and signatures dated 08/14/2025.
Primecap Management Co./CA reports beneficial ownership of 4,878,037 shares of Rhythm Pharmaceuticals, representing 7.67% of the common stock. The filing is an Amendment No. 10 to a Schedule 13G and lists an event date of 06/30/2025. Primecap reports sole voting and sole dispositive power over these shares, and certifies the shares were acquired and are held in the ordinary course of business and not to change or influence control of the issuer. The filing names Rhythm Pharmaceuticals' principal executive offices at the address provided and shows Primecap's business address in Pasadena, California. The form is signed by Jorge A. Rodriguez, Deputy Chief Compliance Officer, dated 08/13/2025.
Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals (RYTM), exercised 3,984 stock options with an exercise price of $6.80 per share and immediately sold those 3,984 shares at a weighted average price of $90.0832 on 08/11/2025. The sale was effected pursuant to a Rule 10b5-1 trading instruction adopted on 08/08/2024.
After these transactions, Shulman's reported direct beneficial ownership of common stock declined from 12,493 shares to 8,509 shares. The Form 4 also reports 7,969 stock options outstanding following the transactions.
Rhythm Pharmaceuticals (RYTM) filed a Form 144 reporting a proposed sale of 28,088 common shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $2,648,979.28. The filing states these shares were acquired the same day by exercise of stock options and paid in cash, indicating an immediate disposition of newly exercised options rather than a transfer from a third party.
The filing does not name the person for whose account the proposed sale is to be made in the main table, though the filing discloses two prior 10b5-1 sales attributed to Hunter Smith totaling 65,520 shares and gross proceeds of $4,826,766.67 in the past three months. The notice includes the standard representation that the signer is not aware of undisclosed material adverse information and references reliance on any Rule 10b5-1 trading plan if applicable.
Christopher Paul German filed a Form 144 reporting a proposed sale of 1,500 Rhythm Pharmaceuticals (RYTM) common shares acquired by exercising stock options on 08/12/2025. The filing shows the shares were paid for in cash, lists Morgan Stanley Smith Barney LLC as broker, assigns an aggregate market value of $141,465.00, and identifies the planned sale on 08/12/2025 on NASDAQ. The issuer has 66,420,091 shares outstanding. The notice also discloses prior 10b5-1 sales by Mr. German in 06/10/2025 and 07/09/2025, totaling 5,886 shares for $447,233.36 gross proceeds. The form includes the standard insider representation about material nonpublic information.
Rhythm Pharmaceuticals (RYTM) reported a Form 144 notice showing an insider transaction involving common stock. The filing discloses the planned sale of 3,984 shares on 08/11/2025 through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $366,448.32. Those shares were acquired the same day by exercise of stock options from the issuer and paid for in cash.
The filing also lists shares outstanding of 66,420,091, and prior 10b5-1 sales on 07/09/2025 of 7,969 shares for gross proceeds of $619,850.56. The notice includes the standard officer representation about absence of undisclosed material adverse information.
FAQ
What is the current stock price of Rhythm Pharmaceu (RYTM)?
What is the market cap of Rhythm Pharmaceu (RYTM)?
